Cassava Sciences Inc vs Clear Secure Inc — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Clear Secure Inc trades at $43.43 (market cap $4.44B). The key difference: Clear Secure Inc is far larger — about 112.7× Cassava Sciences Inc's market cap, and Clear Secure Inc pays a 1.33% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Clear Secure Inc for 19 Days on average.
| FLNA | YOU | |
|---|---|---|
Market Cap | $39.40M | $4.44B |
Volume | 759,018 | 1,477,828 |
Sector | Health | Technology |
52-Week High | $4.64 | $62.36 |
52-Week Low | $0.68 | $29.61 |
Typical Hold Time | 37 Days | 19 Days |
Enterprise Value | -$43.28M | $3.59B |
Dividend Yield | — | 1.33% |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8168 with minimal daily movement (+0.13%). The stock shows bearish technical signals with negative moving averages but has beaten earnings expectations for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam enables Phase 2a epilepsy trials, providing potential catalyst. However, the company reports zero revenue, negative EBITDA of -$95.19M, and concerning cash flow trends with net cash outflow of -$33.07M in 2025.
While analyst consensus is strongly bullish (67% buy ratings), fundamental weaknesses including negative profitability metrics and cash burn present significant risks. The FDA approval provides near-term optimism for the epilepsy drug pipeline, but execution risk remains high given the company's financial position and lack of current revenue streams.
Clear Secure (YOU) trades at $43.43, up 2.0% today, with a bullish technical signal despite overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates with $0.49 versus $0.40 expected, and revenue growth accelerated to 27% year-over-year. Analyst consensus is mixed with a $61.40 price target, and the stock shows robust profitability with a 90.29% ROE and expanding margins.
The outlook is positive given membership growth and new enterprise initiatives, but risks include high valuation multiples and insider selling. The stock offers growth potential driven by identity platform expansion, though investors should weigh competitive pressures and execution risks against strong fundamental trends.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →